Buchumschlag

FGFR2 inhibition in Cholangiocarcinoma

Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vogel, Arndt (VerfasserIn) , Segatto, Oreste (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Saborowski, Anna (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2023
In: Annual review of medicine
Year: 2023, Jahrgang: 74, Pages: 293-306
ISSN:1545-326X
DOI:10.1146/annurev-med-042921-024707
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1146/annurev-med-042921-024707
Verlag, kostenfrei, Volltext: https://www.annualreviews.org/doi/10.1146/annurev-med-042921-024707
Volltext
Verfasserangaben:Arndt Vogel, Oreste Segatto, Albrecht Stenzinger, and Anna Saborowski

MARC

LEADER 00000caa a2200000 c 4500
001 1839777699
003 DE-627
005 20230706215527.0
007 cr uuu---uuuuu
008 230322s2023 xx |||||o 00| ||eng c
024 7 |a 10.1146/annurev-med-042921-024707  |2 doi 
035 |a (DE-627)1839777699 
035 |a (DE-599)KXP1839777699 
035 |a (OCoLC)1389531105 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Vogel, Arndt  |d 1971-  |e VerfasserIn  |0 (DE-588)12366960X  |0 (DE-627)082697256  |0 (DE-576)293818622  |4 aut 
245 1 0 |a FGFR2 inhibition in Cholangiocarcinoma  |c Arndt Vogel, Oreste Segatto, Albrecht Stenzinger, and Anna Saborowski 
264 1 |c 2023 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published as a review in advance on September 28, 2022 
500 |a Gesehen am 22.03.2023 
520 |a Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder carcinoma. While the mutational profiles in these anatomical BTC subtypes overlap to a large extent, iCCA is notable for the high frequency of IDH1/2 mutations (10-22%) and the nearly exclusive occurrence of FGFR2 fusions in 10-15% of patients. In recent years, FGFR2 fusions have become one of the most promising targets for precision oncology targeting BTC, with FGFR inhibitors already approved in Europe and the United States for patients with advanced, pretreated iCCA. While the therapeutic potential of nonfusion alterations is still under debate, it is expected that the field of FGFR2-directed therapies will be subject to rapid further evolution and optimization. The scope of this review is to provide an overview of oncogenic FGFR signaling in iCCA cells and highlight the pathophysiology, diagnostic testing strategies, and therapeutic promises and challenges associated with FGFR2-altered iCCA. 
700 1 |a Segatto, Oreste  |e VerfasserIn  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Saborowski, Anna  |d 1981-  |e VerfasserIn  |0 (DE-588)134222571  |0 (DE-627)563029390  |0 (DE-576)30038579X  |4 aut 
773 0 8 |i Enthalten in  |t Annual review of medicine  |d Palo Alto, Calif. : Annual Reviews, 1950  |g 74(2023), Seite 293-306  |h Online-Ressource  |w (DE-627)300184298  |w (DE-600)1481484-5  |w (DE-576)094531196  |x 1545-326X  |7 nnas  |a FGFR2 inhibition in Cholangiocarcinoma 
773 1 8 |g volume:74  |g year:2023  |g pages:293-306  |g extent:17  |a FGFR2 inhibition in Cholangiocarcinoma 
856 4 0 |u https://doi.org/10.1146/annurev-med-042921-024707  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.annualreviews.org/doi/10.1146/annurev-med-042921-024707  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20230322 
993 |a Article 
994 |a 2023 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 3 
999 |a KXP-PPN1839777699  |e 4294902981 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"note":["Gesehen am 19.01.05"],"pubHistory":["1.1950 -"],"part":{"volume":"74","year":"2023","pages":"293-306","extent":"17","text":"74(2023), Seite 293-306"},"language":["eng"],"titleAlt":[{"title":"Annual reviews / Biomedical sciences / Annual review of medicine"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"FGFR2 inhibition in CholangiocarcinomaAnnual review of medicine","recId":"300184298","origin":[{"dateIssuedKey":"1950","publisherPlace":"Palo Alto, Calif.","publisher":"Annual Reviews","dateIssuedDisp":"1950-"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1545-326X"],"eki":["300184298"],"zdb":["1481484-5"]},"title":[{"title_sort":"Annual review of medicine","title":"Annual review of medicine"}]}],"origin":[{"dateIssuedDisp":"2023","dateIssuedKey":"2023"}],"title":[{"title_sort":"FGFR2 inhibition in Cholangiocarcinoma","title":"FGFR2 inhibition in Cholangiocarcinoma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"17 S."}],"id":{"doi":["10.1146/annurev-med-042921-024707"],"eki":["1839777699"]},"person":[{"role":"aut","family":"Vogel","given":"Arndt","display":"Vogel, Arndt"},{"given":"Oreste","display":"Segatto, Oreste","role":"aut","family":"Segatto"},{"role":"aut","family":"Stenzinger","given":"Albrecht","display":"Stenzinger, Albrecht"},{"given":"Anna","display":"Saborowski, Anna","family":"Saborowski","role":"aut"}],"recId":"1839777699","note":["First published as a review in advance on September 28, 2022","Gesehen am 22.03.2023"],"name":{"displayForm":["Arndt Vogel, Oreste Segatto, Albrecht Stenzinger, and Anna Saborowski"]},"language":["eng"]} 
SRT |a VOGELARNDTFGFR2INHIB2023 

Ähnliche Einträge